JP2002515875A - 躁鬱双極性障害の処置のための薬剤製造のためのトピラメート又はその誘導体の使用 - Google Patents

躁鬱双極性障害の処置のための薬剤製造のためのトピラメート又はその誘導体の使用

Info

Publication number
JP2002515875A
JP2002515875A JP50424298A JP50424298A JP2002515875A JP 2002515875 A JP2002515875 A JP 2002515875A JP 50424298 A JP50424298 A JP 50424298A JP 50424298 A JP50424298 A JP 50424298A JP 2002515875 A JP2002515875 A JP 2002515875A
Authority
JP
Japan
Prior art keywords
formula
topiramate
treatment
bipolar disorder
depressive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP50424298A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002515875A5 (https=
Inventor
シヤンク，リチヤード・ピー
Original Assignee
オーソ―マクニール・フアーマシユーチカル・インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オーソ―マクニール・フアーマシユーチカル・インコーポレーテツド filed Critical オーソ―マクニール・フアーマシユーチカル・インコーポレーテツド
Publication of JP2002515875A publication Critical patent/JP2002515875A/ja
Publication of JP2002515875A5 publication Critical patent/JP2002515875A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04N—PICTORIAL COMMUNICATION, e.g. TELEVISION
    • H04N21/00—Selective content distribution, e.g. interactive television or video on demand [VOD]
    • H04N21/40—Client devices specifically adapted for the reception of or interaction with content, e.g. set-top-box [STB]; Operations thereof
    • H04N21/43—Processing of content or additional data, e.g. demultiplexing additional data from a digital video stream; Elementary client operations, e.g. monitoring of home network or synchronising decoder's clock; Client middleware
    • H04N21/442—Monitoring of processes or resources, e.g. detecting the failure of a recording device, monitoring the downstream bandwidth, the number of times a movie has been viewed, the storage space available from the internal hard disk
    • H04N21/44213—Monitoring of end-user related data
    • H04N21/44222—Analytics of user selections, e.g. selection of programmes or purchase activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Social Psychology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Signal Processing (AREA)
  • Databases & Information Systems (AREA)
  • Multimedia (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP50424298A 1996-06-28 1997-06-24 躁鬱双極性障害の処置のための薬剤製造のためのトピラメート又はその誘導体の使用 Ceased JP2002515875A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US2085096P 1996-06-28 1996-06-28
US60/020,580 1996-06-28
US08/881,008 US5753693A (en) 1996-06-28 1997-06-23 Anticonvulsant derivatives useful in treating manic-depressive bipolar disorder
PCT/US1997/010949 WO1998000123A1 (en) 1996-06-28 1997-06-24 Use of topiramate or derivatives thereof for the manufacture of a medicament for the treatment of manic-depressive bipolar disorders

Publications (2)

Publication Number Publication Date
JP2002515875A true JP2002515875A (ja) 2002-05-28
JP2002515875A5 JP2002515875A5 (https=) 2005-03-10

Family

ID=26693960

Family Applications (1)

Application Number Title Priority Date Filing Date
JP50424298A Ceased JP2002515875A (ja) 1996-06-28 1997-06-24 躁鬱双極性障害の処置のための薬剤製造のためのトピラメート又はその誘導体の使用

Country Status (21)

Country Link
US (1) US5753693A (https=)
EP (1) EP0932398B1 (https=)
JP (1) JP2002515875A (https=)
KR (1) KR20000022233A (https=)
CN (1) CN1224350A (https=)
AP (1) AP1401A (https=)
AT (1) ATE330593T1 (https=)
AU (1) AU739363B2 (https=)
BR (1) BR9712783A (https=)
CA (1) CA2258895C (https=)
CZ (1) CZ297342B6 (https=)
DE (1) DE69736183T2 (https=)
ES (1) ES2267144T3 (https=)
HU (1) HUP0003381A3 (https=)
IL (1) IL127714A (https=)
NO (1) NO317641B1 (https=)
NZ (1) NZ333565A (https=)
RU (1) RU2185824C2 (https=)
SK (1) SK180498A3 (https=)
WO (1) WO1998000123A1 (https=)
ZA (1) ZA975773B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009520034A (ja) * 2005-12-19 2009-05-21 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 鬱病を治療するためのベンゾ縮合複素環スルファミド誘導体の使用
JP2009520030A (ja) * 2005-12-19 2009-05-21 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 躁病および双極性障害を治療するためのベンゾ縮合複素環スルファミド誘導体の使用

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1143917T3 (da) 1998-11-17 2004-06-01 Ortho Mcneil Pharm Inc Antikonvulsive derivater egnet til behandling af posttraumatisk stresssygdom
CA2319646A1 (en) * 1998-12-03 2000-06-08 Ortho-Mcneil Pharmaceutical, Inc. Topiramate and related derivatives for treating schizophrenia
EP1152756B1 (en) 1999-02-08 2005-07-13 Ortho-McNeil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating autism
ATE294577T1 (de) 1999-02-24 2005-05-15 Univ Cincinnati Verwendung von sulfamat derivaten zur behandlung von impulsiven störungen
WO2000061138A1 (en) * 1999-04-08 2000-10-19 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating chronic neurodegenerative disorders
US6420369B1 (en) 1999-05-24 2002-07-16 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating dementia
US20080103179A1 (en) * 2006-10-27 2008-05-01 Tam Peter Y Combination Therapy
US7659256B2 (en) * 1999-06-14 2010-02-09 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US7674776B2 (en) 1999-06-14 2010-03-09 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US7553818B2 (en) * 1999-06-14 2009-06-30 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US20080255093A1 (en) * 1999-06-14 2008-10-16 Tam Peter Y Compositions and methods for treating obesity and related disorders
WO2000076493A1 (en) 1999-06-14 2000-12-21 Thomas Najarian Combination therapy for effecting weight loss and treating obesity
US7056890B2 (en) 1999-06-14 2006-06-06 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US6191117B1 (en) * 2000-07-10 2001-02-20 Walter E. Kozachuk Methods of producing weight loss and treatment of obesity
EP1309325A1 (en) 2000-08-02 2003-05-14 Ortho-McNeil Pharmaceutical, Inc. Anticonvulsant derivatives useful for the treatment of depression
EP1345602B1 (en) 2000-11-30 2010-07-21 Novodermix International Limited Wound healing
US7041650B2 (en) * 2001-07-09 2006-05-09 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivative salts
CA2459146A1 (en) * 2001-08-30 2003-03-13 Ortho-Mcneil Pharmaceutical, Inc. Treatment of dementia and memory disorders with anticonvulsants and acetylcholinesterase inhibitors
WO2003032974A2 (en) * 2001-10-12 2003-04-24 Eli Lilly And Company Use of sulfonamide derivatives as pharmaceuticals compounds
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US20100311701A1 (en) * 2002-02-15 2010-12-09 Transform Pharmaceuticals, Inc Pharmaceutical Co-Crystal Compositions
US6559293B1 (en) * 2002-02-15 2003-05-06 Transform Pharmaceuticals, Inc. Topiramate sodium trihydrate
US20090088443A1 (en) * 2002-02-15 2009-04-02 Julius Remenar Novel crystalline forms of conazoles and methods of making and using the same
US7790905B2 (en) * 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
AU2003213719A1 (en) * 2002-03-01 2003-09-16 Regents Of The University Of Michigan Multiple-component solid phases containing at least one active pharmaceutical ingredient
US20070059356A1 (en) * 2002-05-31 2007-03-15 Almarsson Oern Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
IL165383A0 (en) * 2002-06-21 2006-01-15 Transform Pharmaceuticals Inc Pharmaceutical compositions with improved dissolution
CA2494233A1 (en) * 2002-07-29 2004-02-05 Alza Corporation Formulations and dosage forms for controlled delivery of topiramate
US7196209B2 (en) * 2002-10-31 2007-03-27 Ortho-Mcneil Pharmaceutical, Inc. Continuous process for the preparation of fructopyranose sulfamate derivatives
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
US20050070524A1 (en) * 2003-06-06 2005-03-31 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and an anticonvulsant agent for the treatment of central nervous system disorders
MXPA06007510A (es) * 2003-12-29 2009-06-10 Johnson & Johnson Composiciones de farmaco y formas de dosis novedosas de topiramato.
MY147767A (en) * 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
AR049646A1 (es) * 2004-06-16 2006-08-23 Janssen Pharmaceutica Nv Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados
DE602005008084D1 (de) * 2004-08-24 2008-08-21 Janssen Pharmaceutica Nv Als antikonvulsive mittel geeignete neue benzokondensierte heteroarylsulfamidderivate
KR20080012360A (ko) * 2005-05-20 2008-02-11 얀센 파마슈티카 엔.브이. 설파미드 유도체의 제조 방법
US20070155823A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
US8497298B2 (en) * 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US8492431B2 (en) * 2005-12-19 2013-07-23 Janssen Pharmaceutica, N.V. Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
US8716231B2 (en) * 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US8691867B2 (en) * 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US20070191474A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine
US20070191450A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Mania and Bipolar Disorder
US20070191449A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Depression
EA200870556A1 (ru) * 2006-05-19 2009-06-30 Янссен Фармацевтика Н.В. Комбинированная терапия в лечении эпилепсии и родственных расстройств
WO2008027557A2 (en) * 2006-08-31 2008-03-06 Spherics, Inc. Topiramate compositions and methods of enhancing its bioavailability
US8298576B2 (en) 2006-11-17 2012-10-30 Supernus Pharmaceuticals, Inc. Sustained-release formulations of topiramate
MX2009003911A (es) 2006-12-04 2009-05-28 Supernus Pharmaceuticals Inc Formulaciones de liberacion inmediata, mejoradas de topiramato.
US20090247617A1 (en) * 2008-03-26 2009-10-01 Abdel-Magid Ahmed F Process for the preparation of benzo-fused heteroaryl sulfamates
US20090247616A1 (en) * 2008-03-26 2009-10-01 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of anxiety
US8580298B2 (en) 2008-06-09 2013-11-12 Vivus, Inc. Low dose topiramate/phentermine composition and methods of use thereof
US20090304789A1 (en) * 2008-06-09 2009-12-10 Thomas Najarian Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders
EA018567B1 (ru) 2008-06-23 2013-08-30 Янссен Фармацевтика Нв Кристаллическая форма (2s)-(-)-n-(6-хлор-2,3-дигидробензо[1,4]диоксин-2-илметил)сульфамида
US8815939B2 (en) * 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
EP3883546A1 (en) 2018-11-21 2021-09-29 Rosemont Pharmaceuticals Ltd Oral topiramate suspension formulations with extended shelf stability and enhanced bioavailability

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4513006A (en) * 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
RU2050852C1 (ru) * 1992-06-05 1995-12-27 Замощина Татьяна Алексеевна Способ пролонгирования биологической активности солей лития
US5384327A (en) * 1992-12-22 1995-01-24 Mcneilab, Inc. Anticonvulsant sorbopyranose sulfamates

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009520034A (ja) * 2005-12-19 2009-05-21 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 鬱病を治療するためのベンゾ縮合複素環スルファミド誘導体の使用
JP2009520030A (ja) * 2005-12-19 2009-05-21 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 躁病および双極性障害を治療するためのベンゾ縮合複素環スルファミド誘導体の使用

Also Published As

Publication number Publication date
NO317641B1 (no) 2004-11-29
CZ427798A3 (cs) 1999-08-11
NZ333565A (en) 2000-07-28
IL127714A (en) 2004-08-31
CN1224350A (zh) 1999-07-28
ZA975773B (en) 1998-12-28
DE69736183D1 (de) 2006-08-03
KR20000022233A (ko) 2000-04-25
AP9801427A0 (en) 1998-12-31
CA2258895A1 (en) 1998-01-08
RU2185824C2 (ru) 2002-07-27
US5753693A (en) 1998-05-19
AU739363B2 (en) 2001-10-11
CZ297342B6 (cs) 2006-11-15
CA2258895C (en) 2006-06-06
DE69736183T2 (de) 2007-04-26
AU3409697A (en) 1998-01-21
AP1401A (en) 2005-04-29
ES2267144T3 (es) 2007-03-01
HUP0003381A3 (en) 2001-12-28
IL127714A0 (en) 1999-10-28
EP0932398B1 (en) 2006-06-21
SK180498A3 (en) 2000-03-13
BR9712783A (pt) 2000-10-24
HUP0003381A2 (hu) 2001-05-28
NO986051D0 (no) 1998-12-22
ATE330593T1 (de) 2006-07-15
EP0932398A1 (en) 1999-08-04
WO1998000123A1 (en) 1998-01-08
NO986051L (no) 1999-02-23

Similar Documents

Publication Publication Date Title
JP2002515875A (ja) 躁鬱双極性障害の処置のための薬剤製造のためのトピラメート又はその誘導体の使用
JP2000514425A (ja) 肥満の処置に有用な抗痙攣剤のスルファメート誘導体
US6362220B1 (en) Anticonvulsant derivatives useful in reducing blood glucose levels
JP4825353B2 (ja) 血圧を下げることに有用な抗痙攣薬誘導体
US6191163B1 (en) Anticonvulsant derivatives useful in lowering lipids
US20020052325A1 (en) Anticonvulsant derivatives useful in maintaining weight loss
EP1143917B1 (en) Anticonvulsant derivatives useful in treating post traumatic stress disorder
JP4251410B2 (ja) 乾癬の処置に有用な抗痙攣剤のスルファメート誘導体
KR100496932B1 (ko) 비만치료에유용한항경련성설파메이트유도체
HK1018743B (en) Anticonvulsant sulfamate derivatives useful in treating obesity
JP2003524623A (ja) 血液グルコースレベルを下げることに有用な抗痙攣薬誘導体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040622

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040622

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080212

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20080424

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080509

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080616

A313 Final decision of rejection without a dissenting response from the applicant

Free format text: JAPANESE INTERMEDIATE CODE: A313

Effective date: 20080930

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20081125